Physician profile
Omar Obeidat
NPI 1942274279
$2,497.49
in general payments reported to CMS, 2019-2025
21 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $151 · 2021: $134 · 2022: $185 · 2023: $927 · 2024: $618 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.53 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $972.71 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $265.95 | 2020-2024 | Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $164.39 | 2021-2024 | Xarelto |
| Biosense Webster, INC. | $145.83 | 2025 | Carto 3 |
| Actelion Pharmaceuticals US, INC. | $124.33 | 2023 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $112.46 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $104.03 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $103.14 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $86.86 | 2022-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $63.54 | 2023 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $48.25 | 2023-2024 | Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.77 | 2023 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $41.82 | 2023-2024 | Inpefa |
| Stryker Corporation | $40.52 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sanofi-Aventis U.S. LLC | $38.35 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $35.12 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $33.39 | 2023 | Arcalyst |
| Heartflow, INC. | $21.31 | 2023 | Ffrct |
| Novo Nordisk INC | $20.14 | 2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $18.55 | 2021 | |
| Pfizer INC. | $14.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Obeidat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.